The effect of a topical antioxidant formulation including N-acetyl carnosine on canine cataract: A preliminary study

Veterinary Ophthalmology

Volumn 9, Issue 5, 2006, Pages 311-316

  Williams, David L ^a   Munday, Patricia ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Antioxidant; Cataract; Dog; N acetyl carnosine

Indexed keywords

ANTIOXIDANT; CARNOSINE; EYE DROPS;

ANIMAL; ANIMAL DISEASE; ARTICLE; CATARACT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOG DISEASE; DOUBLE BLIND PROCEDURE; FEMALE; HOSPITALIZATION; MALE; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIOXIDANTS; CARNOSINE; CATARACT; DOG DISEASES; DOGS; DOUBLE-BLIND METHOD; FEMALE; MALE; OPHTHALMIC SOLUTIONS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANIMALIA; CANIS FAMILIARIS;

EID: 33747881115     PISSN: 14635216     EISSN: 14635224     Source Type: Journal    
DOI: 10.1111/j.1463-5224.2006.00492.x     Document Type: Article

References (14)

1. Williams DL. Oxidation, antioxidants and cataract formation: a literature review. Veterinary Opbtbalmology 2006; 9: 292-298.
2. Babizhayev MA, Deyev AI, Yermakova VN et al. Lipid peroxidarion and cataracts: N-acetylcarnosine as a therapeutic tool to manage age-related cataracts in human and in canine eyes. Drugs R and D 2004; 5: 125-139.
3. Babizhayev MA, Deyev AI, Yermakova VN et al. Efficacy of N-acetylcamosine in the treatment of cataracts. Drugs R and D 2002; 3:87-103.
4. Babizhayev MA, Deyev AI, Yermakova VN et al. N-acetylcarnosine, a natural histidine-containing dipeptide, as a potent ophthalmic drug in treatment of human cataracts. Petides 2001; 22: 979-994.
5. Seidler NW, Yeargans GS, Morgan TG. Carnosine disaggregates glycated alpha-crystallin: an in vitro study. Archives of Biochemistry and Biophysics 2004; 427: 110-115.
6. Franke S, Dawczynski J, Strobel J etal. Increased levels of advanced glycation end products in human cataractous lenses. Journal of Cataract and Refractive Surgery 2003; 29: 998-1004.
7. Yan H, Harding JJ. Carnosine protects against the inactivation of esterase induced by glycation and a steroid. Biochemica Biophysica Acta 2005; 1741: 120-126.
8. Hipkiss AR, Preston JE, Himsworth DT et al. Pluripotent protective effects of carnosine, a naturally occurring dipeptide. Annals of the New York Academy of Sciences 1998; 854: 37-53.
9. Decker EA, Livisay SA, Zhou S. A re-evaluation of die antioxidant activity of purified carnosine. Biochemistry (Moscow) 2000; 65: 766-770.
10. McFarland GA, Holliday R. Retardation of the senescence of cultured human diploid fibroblasts by carnosine. Experimental Cell Research 1994; 212: 167-175.
11. Babizhayev MA, Yermakova VN, Sakina NL et al. N-alpha-acetylcarnosine is a prodrug of 1-carnosine in ophthalmic application as antioxidant. Clinica Chimica Acta 1996; 254: 1-21.
12. Chylack LT Jr, Brown NP, Bron A et al. The Roche European American cataract trial (REACT): a randomized clinical trial to investigate the efficacy of an oral antioxidant micronutrient mixture to slow progression of age-related cataract. Ophthalmic Epidemiology 2002; 9: 49-80.
13. Murdoch IE, Morris SS, Cousens SN. People and eyes: statistical approaches in ophthalmology. British Journal of Ophthalmology 1998; 82: 971-973.
14. Sharma YR, Vajpayee RB, Bhatnagar R et al. Topical glutathione therapy in senile cataracts. Cataract-III. Indian Journal of Ophthalmology 1989; 37: 121-126.